{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.0","upperLimit":"18.5","value":"14.9"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"8.2","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the date of the first documented disease progression (PD) or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC/central review and survival information. If a participant did not had an event at the time of the analysis cut-off or at the start of any new anti-cancer therapy, data was censored at the date of last adequate tumor assessment. PD was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 square millimeter (mm\\^2).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 450 milligram (mg) of LGX818 orally once daily (QD) along with 45 mg of MEK162 twice daily (BID) for each 28 day treatment cycle until progressive disease (PD) as confirmed by Blinded Independent Review Committee (BIRC), withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)"},{"description":"Participants received 960 mg of Vemurafenib according to the locally approved prescribing information twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 1: Vemurafenib 960 mg BID"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months)","title":"Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group","type":"PRIMARY","unitOfMeasure":"Months"}